Elicit: Resistance Mechanisms in Enzalutamide Therapy
Resistance Mechanisms in Enzalutamide Therapy
What resistance mechanisms emerge during enzalutamide therapy?
Enzalutamide resistance mechanisms include AR pathway alterations (amplifications, mutations, splice variants), bypass signaling pathways (JAK2-STAT5, glucocorticoid receptor), metabolic adaptations (AKR1C3, HMGCR), and lineage plasticity, primarily through clonal selection of pre-existing heterogeneity rather than newly acquired mutations.
Abstract
Resistance to enzalutamide in castration-resistant prostate cancer involves multiple mechanisms operating at both androgen receptor-dependent and AR-independent levels. AR pathway alterations represent the most extensively validated resistance mechanisms, with AR amplifications increasing from 53.9% at baseline to 64.7% at progression, specific AR mutations (H875Y, F877L, T878A/S) detected in approximately 15% of patients with progressive disease, and AR-V7 splice variants rising from 29% at baseline to 40% during treatment. However, a substantial proportion of resistance mechanisms are pre-existing rather than purely acquired, with 73.1% of baseline biopsies showing AR pathway alterations and 92.3% harboring tumor suppressor mutations (PTEN, RB1, TP53), indicating that clonal selection during treatment intensifies pre-existing heterogeneity. Bypass signaling pathways emerge as alternative resistance mechanisms, including JAK2-STAT5 activation through a positive feed-forward loop induced by enzalutamide-liganded AR, glucocorticoid receptor upregulation confirmed in clinical samples, and metabolic adaptations involving AKR1C3 and HMGCR that enable intracrine androgen synthesis. The spectrum of resistance mechanisms varies by prior treatment exposure, with specific AR mutations (L702H, T878A) enriched in abiraterone-pretreated patients, and by disease duration, with lineage plasticity toward neuroendocrine differentiation emerging under sustained AR suppression. Therapeutic strategies targeting these mechanisms include combination approaches with PARP inhibitors (TALAPRO-2 trial), EZH2 inhibitors (MEVPRO-2 trial), JAK2 inhibitors, and metabolic pathway inhibitors including statins and indomethacin.
Methods
We analyzed 10 sources from an initial pool of 200, using 7 screening criteria. Each paper was reviewed for 6 key aspects that mattered most to the research question.
Records from Elicit search
- n = 200
- Papers screened using: Enzalutamide Treatment, Resistance Mechanisms, Patient Population, Study Design, Acquired Resistance Focus, Enzalutamide-Specific Focus, Sample Size Adequacy
- n = 200
- Papers screened out
- n = 190
- Papers included for extraction
- n = 10
Resistance Mechanisms
Androgen Receptor-Dependent Mechanisms
| Mechanism | Type of Alteration | Clinical Validation | Timing of Emergence |
|---|---|---|---|
| AR amplification | Copy number gain | Detected in 53.9% at baseline, 64.7% at progression; associated with worse progression-free survival (HR 2.92) | Both pre-existing and acquired |
| AR mutations (H875Y, F877L, T878A/S) | Point mutations in ligand-binding domain | Observed in ~15% of progressive mCRPC patients; F877L and T878A mutations increase during treatment | Primarily acquired during treatment |
| AR splice variants (AR-V7) | Constitutively active truncated variants | Detected in 29% at baseline, 40% at progression; associated with shorter survival and lower PSA response rates | Both pre-existing and acquired |
| Heavily mutated AR (≥2 mutations) | Multiple mutations | Associated with worse progression-free survival (HR 3.94) | Acquired during treatment |
Bypass Signaling Pathways
Glucocorticoid Receptor Pathway
Glucocorticoid receptor (GR) upregulation was identified as a key bypass mechanism. GR can activate AR target genes through an alternative pathway.
JAK2-STAT5 Signaling
Enzalutamide-liganded AR induces sustained JAK2-STAT5 phosphorylation, creating a positive feed-forward loop where activated STAT5 increases JAK2 mRNA and protein levels, further activating JAK2.
PI3K/Akt/mTOR Pathway
AR inhibition increases active Akt, contributing to oncogenic pathways and regulates AR protein levels.
Tumor Suppressor Loss and Lineage Plasticity
| Alteration | Frequency | Clinical Correlation | Mechanism |
|---|---|---|---|
| PTEN loss | Present in 92.3% of baseline biopsies | Associated with resistance | Affects AR signaling pathway |
| RB1 loss | Present in 92.3% of baseline biopsies; 13/63 baseline samples | Associated with worse progression-free survival (HR 4.46) | Drives lineage plasticity toward AR-independent neuroendocrine phenotype |
| TP53 loss | Present in 92.3% of baseline biopsies | Associated with resistance | Drives lineage plasticity |
This detailed analysis provides major insights into the mechanisms driving resistance to enzalutamide therapy in CRPC patients.
The emergence of resistance mechanisms emphasizes the need for tailored therapeutic strategies in managing this challenging condition.